[Asia Economy Reporter Hyunseok Yoo] Hanmi Pharm is showing strong performance. The news that it can supply up to 300 million doses of mRNA raw materials within 12 months seems to have had an impact.
As of 2:09 PM on the 1st, Hanmi Pharm was traded at 351,000 KRW, up 4.93% (16,500 KRW) compared to the previous trading day.
The Korea National Institute of Health announced on the same day that it had inspected the technology of Hanmi Precision Chemical, which recently succeeded in synthesizing six key mRNA raw materials. Hanmi Precision Chemical is a raw material pharmaceutical company affiliated with the Hanmi Pharm Group.
The on-site verification was attended by Kwon Jun-wook, Director of the Korea National Institute of Health, and Kim Do-geun, Head of the Infectious Disease Vaccine Research Division. From the Hanmi Pharm Group, attendees included Lim Jong-yoon, Chairman of the Bio Association, Kim Su-jin, Executive Director of Hanmi Pyeongtaek Bio Plant, Jang Young-gil, CEO of Hanmi Precision Chemical, Lee Jae-heon, Director of Hanmi Precision Chemical Research Institute, and Kwon Kyu-chan, Executive Director in charge of Overseas RA at Hanmi Pharm.
Director Kwon Jun-wook visited the site to confirm the potential for mass production of six key mRNA raw materials and Korea’s potential as a gene vaccine production hub. He also urged continuous accumulation of R&D capabilities to secure national vaccine sovereignty.
Lim Jong-yoon, Chairman of the Bio Association (CEO of Hanmi Science), responded “practically yes” to Director Kwon’s question, “Can we consider Hanmi as the only company in Korea currently capable of producing mRNA?” He added, “Although monthly production volumes may vary, Hanmi can immediately supply raw materials for up to 300 million doses within 12 months and can rapidly supply mRNA key raw materials, which are in global shortage.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
